Industry Assesses Threat From Drug-Pricing Debate
Drug pricing and government oversight were raised as critical issues for the industry in panels, presentations and conversations throughout the BIO CEO & Investor conference, with opinions varying on how much of a threat it could be.
You may also be interested in...
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.
First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.
Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.